BIT Capital Reports 5.9% Stake In Compass Pathways, 8.1 Million Shares
The Berlin investment firm holds 8,148,280 ADSs and certified they are not held to influence control of the psilocybin developer.
BIT Capital, a Berlin investment firm, holds 8,148,280 American Depositary Shares of Compass Pathways, or 5.9% of the class, according to a passive ownership filing (Schedule 13G) dated Wednesday. Compass, which develops a psilocybin treatment for depression, reports third-quarter results on November 3.
A passive stake with sole voting power
The holding is as of September 30, 2026, and BIT Capital GmbH has sole voting power over all 8,148,280 shares. It reports the position through its investment discretion over portfolios it manages under discretionary mandates. Each ADS represents one ordinary share.
The 5.9% figure is rounded; the calculated percentage is about 5.88%. It rests on 138,476,822 ordinary shares outstanding as of July 30, 2026, the count in Compass's 10-Q for the quarter ended June 30, 2026.
BIT Capital certified that it acquired and holds the shares in the ordinary course of business, not to change or influence control of the company. The firm is registered as a German investment firm under section 2, paragraph 1 of the country's WpIG investment-firm law.
A psilocybin developer with no approved product
Compass Pathways is a biotechnology company developing COMP360, an investigational psilocybin treatment, for serious mental health conditions that current treatments do not help. Its first focus is treatment-resistant depression, and it is also pursuing post-traumatic stress disorder. It has no approved products.
The company says COMP360 holds FDA Breakthrough Therapy designation for treatment-resistant depression. Its shares traded at $11.87 in Wednesday trading, up about 0.5% from the prior close of $11.81, for a market value of about $1.6 billion.
Earnings on November 3
Compass will report third-quarter results on November 3, 2026, with a conference call at 8:00 a.m. ET.
BIT Capital's stake will next be tested against Compass's third-quarter report on November 3.
Sources
- SCHEDULE 13G — BIT Capital GmbH re: COMPASS Pathways plc (CMPS) — SEC EDGAR
- Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026 – Company Announcement - FT.com — Financial Times
- Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress – Company Announcement - FT.com — Financial Times